Category survey

Targeting the apoE/A-beta Interaction as a Therapeutic Approach for AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimers Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Misfolded protein-clearance enhancers for Alzheimers therapy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

DEVELOPMENT OF NOVEL THERAPEUTIC ANTI-TAU ANTIBODIES Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Integrative Biology Approach to Complexity of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

SORT1:PGRN blocking antibodies for Frontotemporal dementia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Integrative Biology Approach to Complexity of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Discovery of Novel Proteomic Targets for Treatment of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Discovery of probes that enhance expression of the neuroprotective protein Klotho Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

A system approach to targeting innate immunity in AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Development of novel inhibitors of C1q for the treatment of Neurodegenerative diseases Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The Olfactory Bulb-Entorhinal Cortex Axis as an Early Biomarker for Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Development of an ophthalmic diagnostic probe for neurodegenerativedisorders Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Pathogenesis of Postoperative Cognitive Dysfunction Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Synaptic substrates of age-dependent memory deficits Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mechanisms transducing insulin and insulin resistance in the hippocampus Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Translating CD33 genetic mechanism into a novel Alzheimers therapeutic Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Characterizing novel hippocampal drugs for Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Restoring Brain Functions in Alzheimer Models with Interneuron Transplants Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Drug Discovery against the Early, Secreted and Toxic Tau in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Intranasal Insulin in a Mouse Model of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Novel Strategies and Mechanisms to Target APOE and Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimers Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Novel bivalent multifunctional ligands towards Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Intranasal Delivery of Peptide Drugs to the Brain Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Lead optimization of somatostatin-based therapeutic for Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Discovery of Novel Proteomic Targets for Treatment of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

A Translational Program of BDNF Gene Delivery in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

DEVELOPMENT OF NOVEL THERAPEUTIC ANTI-TAU ANTIBODIES Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

ApoE4-targeted therapeutics that normalize SirT1 Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

A system approach to targeting innate immunity in AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Integrative Biology Approach to Complexity of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment. Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMER’S DISEASE Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Therapeutic potential of GMF suppresssion in inflammation and neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Plasticity circuits in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Allopregnanolone a Regenerative Therapy for Alzheimers: FDA-Required Toxicolog Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Brain-Gut Communication in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of CK2 in NMDAR trafficking during development and in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Cholesterol and Sphingolipid Metabolism in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

RNA binding proteins as novel targets in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Multi-level Integrative Proteomics to Alzheimers Disease Pathways Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Molecular Characterization and Validation of Gender Differences in Alzheimers Disease Pathogenesis Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The IU/JAX Alzheimers Disease Precision Models Center Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Interdisciplinary Research to Understand the Interplay of Diabetes, Cerebrovascular disease and Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Community based assessments regarding vascular contributions to Alzheimers Disease in M2OVE AD consortium Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Development of EP2 receptor antagonists for suppression of Alzheimers neuropathology Investments > €500k United States of America Alzheimer’s disease & other dementias 2016